Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Common Equity (2018 - 2025)

China SXT Pharmaceuticals has reported Common Equity over the past 8 years, most recently at $15.4 million for Q1 2025.

  • For Q1 2025, Common Equity rose 10.83% year-over-year to $15.4 million; the TTM value through Mar 2025 reached $15.4 million, up 10.83%, while the annual FY2025 figure was $15.4 million, 10.83% up from the prior year.
  • Common Equity for Q1 2025 was $15.4 million at China SXT Pharmaceuticals, up from $13.9 million in the prior quarter.
  • Over five years, Common Equity peaked at $16.1 million in Q1 2022 and troughed at $13.9 million in Q1 2024.
  • A 5-year average of $15.2 million and a median of $15.4 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 69.78% in 2021 and later fell 8.65% in 2023.
  • Year by year, Common Equity stood at $16.0 million in 2021, then rose by 0.76% to $16.1 million in 2022, then dropped by 8.65% to $14.7 million in 2023, then decreased by 5.18% to $13.9 million in 2024, then increased by 10.83% to $15.4 million in 2025.
  • Business Quant data shows Common Equity for SXTC at $15.4 million in Q1 2025, $13.9 million in Q1 2024, and $14.7 million in Q1 2023.